vs
GLOBUS MEDICAL INC（GMED）与Rivian Automotive, Inc.（RIVN）财务数据对比。点击上方公司名可切换其他公司
Rivian Automotive, Inc.的季度营收约是GLOBUS MEDICAL INC的1.6倍（$1.3B vs $826.4M），GLOBUS MEDICAL INC净利率更高（17.0% vs -63.1%，领先80.1%），GLOBUS MEDICAL INC同比增速更快（25.7% vs -25.8%），GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-1.1B），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 3.3%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
Rivian Automotive是2009年成立的美国电动汽车制造商及汽车科技企业，主打基于自研滑板平台打造的电动SUV、皮卡及EDV电动配送货车，旗下R1T皮卡于2021年末正式开启交付，还计划于2023年底前在美国和加拿大布局专属充电网络，其平台可适配新车型也可对外授权使用。
GMED vs RIVN — 直观对比
营收规模更大
RIVN
是对方的1.6倍
$826.4M
营收增速更快
GMED
高出51.6%
-25.8%
净利率更高
GMED
高出80.1%
-63.1%
自由现金流更多
GMED
多$1.3B
$-1.1B
两年增速更快
GMED
近两年复合增速
3.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $1.3B |
| 净利润 | $140.6M | $-811.0M |
| 毛利率 | 68.4% | 9.3% |
| 营业利润率 | 20.5% | -64.8% |
| 净利率 | 17.0% | -63.1% |
| 营收同比 | 25.7% | -25.8% |
| 净利润同比 | 430.4% | -9.0% |
| 每股收益（稀释后） | $1.01 | $-0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDRIVN
| Q4 25 | $826.4M | $1.3B | ||
| Q3 25 | $769.0M | $1.6B | ||
| Q2 25 | $745.3M | $1.3B | ||
| Q1 25 | $598.1M | $1.2B | ||
| Q4 24 | $657.3M | $1.7B | ||
| Q3 24 | $625.7M | $874.0M | ||
| Q2 24 | $629.7M | $1.2B | ||
| Q1 24 | $606.7M | $1.2B |
净利润GMEDRIVN
| Q4 25 | $140.6M | $-811.0M | ||
| Q3 25 | $119.0M | $-1.2B | ||
| Q2 25 | $202.8M | $-1.1B | ||
| Q1 25 | $75.5M | $-545.0M | ||
| Q4 24 | $26.5M | $-744.0M | ||
| Q3 24 | $51.8M | $-1.1B | ||
| Q2 24 | $31.8M | $-1.5B | ||
| Q1 24 | $-7.1M | $-1.4B |
毛利率GMEDRIVN
| Q4 25 | 68.4% | 9.3% | ||
| Q3 25 | 67.2% | 1.5% | ||
| Q2 25 | 66.6% | -15.8% | ||
| Q1 25 | 67.3% | 16.6% | ||
| Q4 24 | 59.9% | 9.8% | ||
| Q3 24 | 56.8% | -44.9% | ||
| Q2 24 | 58.7% | -38.9% | ||
| Q1 24 | 60.2% | -43.8% |
营业利润率GMEDRIVN
| Q4 25 | 20.5% | -64.8% | ||
| Q3 25 | 17.9% | -63.1% | ||
| Q2 25 | 10.2% | -85.5% | ||
| Q1 25 | 16.2% | -52.8% | ||
| Q4 24 | 9.2% | -38.1% | ||
| Q3 24 | 7.7% | -133.8% | ||
| Q2 24 | 7.9% | -118.7% | ||
| Q1 24 | 1.3% | -123.3% |
净利率GMEDRIVN
| Q4 25 | 17.0% | -63.1% | ||
| Q3 25 | 15.5% | -75.3% | ||
| Q2 25 | 27.2% | -85.7% | ||
| Q1 25 | 12.6% | -44.0% | ||
| Q4 24 | 4.0% | -42.9% | ||
| Q3 24 | 8.3% | -125.9% | ||
| Q2 24 | 5.0% | -125.8% | ||
| Q1 24 | -1.2% | -120.1% |
每股收益（稀释后）GMEDRIVN
| Q4 25 | $1.01 | $-0.66 | ||
| Q3 25 | $0.88 | $-0.96 | ||
| Q2 25 | $1.49 | $-0.97 | ||
| Q1 25 | $0.54 | $-0.48 | ||
| Q4 24 | $0.19 | $-0.67 | ||
| Q3 24 | $0.38 | $-1.08 | ||
| Q2 24 | $0.23 | $-1.46 | ||
| Q1 24 | $-0.05 | $-1.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $6.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.6B | $4.6B |
| 总资产 | $5.3B | $14.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GMEDRIVN
| Q4 25 | $557.2M | $6.1B | ||
| Q3 25 | $18.8M | $7.1B | ||
| Q2 25 | — | $7.5B | ||
| Q1 25 | — | $7.2B | ||
| Q4 24 | $890.1M | $7.7B | ||
| Q3 24 | $71.9M | $6.7B | ||
| Q2 24 | $82.5M | $7.9B | ||
| Q1 24 | $80.4M | $7.9B |
总债务GMEDRIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $5.5B | ||
| Q1 24 | — | $4.4B |
股东权益GMEDRIVN
| Q4 25 | $4.6B | $4.6B | ||
| Q3 25 | $4.4B | $5.1B | ||
| Q2 25 | $4.3B | $6.1B | ||
| Q1 25 | $4.1B | $6.2B | ||
| Q4 24 | $4.2B | $6.6B | ||
| Q3 24 | $4.1B | $5.9B | ||
| Q2 24 | $4.0B | $6.8B | ||
| Q1 24 | $3.9B | $8.1B |
总资产GMEDRIVN
| Q4 25 | $5.3B | $14.9B | ||
| Q3 25 | $5.1B | $15.2B | ||
| Q2 25 | $5.0B | $15.6B | ||
| Q1 25 | $4.7B | $15.5B | ||
| Q4 24 | $5.3B | $15.4B | ||
| Q3 24 | $5.1B | $14.3B | ||
| Q2 24 | $5.0B | $15.4B | ||
| Q1 24 | $4.9B | $15.7B |
负债/权益比GMEDRIVN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.81× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $-681.0M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $-1.1B |
| 自由现金流率自由现金流/营收 | 24.5% | -89.0% |
| 资本支出强度资本支出/营收 | 5.6% | 36.0% |
| 现金转化率经营现金流/净利润 | 1.77× | — |
| 过去12个月自由现金流最近4个季度 | $588.8M | $-2.5B |
8季度趋势，按日历期对齐
经营现金流GMEDRIVN
| Q4 25 | $248.6M | $-681.0M | ||
| Q3 25 | $249.7M | $26.0M | ||
| Q2 25 | $77.9M | $64.0M | ||
| Q1 25 | $177.3M | $-188.0M | ||
| Q4 24 | $210.3M | $1.2B | ||
| Q3 24 | $203.7M | $-876.0M | ||
| Q2 24 | $54.3M | $-754.0M | ||
| Q1 24 | $52.4M | $-1.3B |
自由现金流GMEDRIVN
| Q4 25 | $202.4M | $-1.1B | ||
| Q3 25 | $213.9M | $-421.0M | ||
| Q2 25 | $31.3M | $-398.0M | ||
| Q1 25 | $141.2M | $-526.0M | ||
| Q4 24 | $193.2M | $856.0M | ||
| Q3 24 | $161.7M | $-1.2B | ||
| Q2 24 | $26.5M | $-1.0B | ||
| Q1 24 | $23.8M | $-1.5B |
自由现金流率GMEDRIVN
| Q4 25 | 24.5% | -89.0% | ||
| Q3 25 | 27.8% | -27.0% | ||
| Q2 25 | 4.2% | -30.5% | ||
| Q1 25 | 23.6% | -42.4% | ||
| Q4 24 | 29.4% | 49.4% | ||
| Q3 24 | 25.8% | -131.9% | ||
| Q2 24 | 4.2% | -89.6% | ||
| Q1 24 | 3.9% | -126.5% |
资本支出强度GMEDRIVN
| Q4 25 | 5.6% | 36.0% | ||
| Q3 25 | 4.7% | 28.7% | ||
| Q2 25 | 6.2% | 35.5% | ||
| Q1 25 | 6.0% | 27.3% | ||
| Q4 24 | 2.6% | 18.9% | ||
| Q3 24 | 6.7% | 31.7% | ||
| Q2 24 | 4.4% | 24.4% | ||
| Q1 24 | 4.7% | 21.1% |
现金转化率GMEDRIVN
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.10× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 2.35× | — | ||
| Q4 24 | 7.94× | — | ||
| Q3 24 | 3.93× | — | ||
| Q2 24 | 1.71× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
RIVN
| Automotive Segment | $839.0M | 65% |
| Software And Services Segment | $447.0M | 35% |
| Regulatory Credits | $30.0M | 2% |
